PrIMAVeRa 1st annual meeting successfully held in a hybrid event in Verona on 29-30 November 2022
PrIMAVeRa team gathered for the first project annual meeting with around 30 project partners joining in Verona (IT), and virtually.
top of page
‘PrIMAVeRa’ means ‘Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance’.
It is a European project funded by the Innovative Medicines Initiative 2 (IMI2) with the goal of developing an open-source, web-based platform combining mathematical models with a comprehensive epidemiological repository (i.e., with data referring to health and economic outcomes). This platform will aim to enable policymakers to reach data-driven decisions regarding the prioritisation of specific vaccines and monoclonal antibodies (mAbs), informing the strategic allocation of limited resources.
A project sustainability plan will also be designed by the project partners with the goal of providing long-term access to the project results, including the models, once the project has finished.
PRIMAVERA is part of the AMR Accelerator Programme.
 Scientist on Computer_edited_edited |
|---|
 Conference |
 Add a Title |
 icon_PrIMAVeRA_crop |
 Laboratory |
 Drug and Syringe |
 Girl at the Pediatrician |
 Pipetting Samples |
 hand shake_Inno4Vac KoM_Source Wix |
 Add a Title |
 Preventive services |
 Add a Title |
At a glance
Innovations to accelerate vaccine development and manufacture
TIMELINE
01.11.2021-30.11.2026
(5 Years)
COORDINATOR
European Vaccine Initiative (EVI)
FUNDER
Innovative Medicines Initiative 2 (IMI2) and European Federation of Pharmaceutical Industries and Associations (EFPIA)
FUNDING
€9.25 Mio
(€6.5 Mio from IMI2 and €2.75 Mio from EFPIA)
bottom of page